Eli Lilly hikes sales outlook, as CEO says there's room for 'dramatic' obesity market expansion
60-Word AI Digest
Eli Lilly hikes sales outlook, as CEO says there's room for 'dramatic' obesity market expansion. Reporting by CNBC highlights major developments in this space as key stakeholders evaluate broader implications. Further data and contextual analysis are actively being published. Access the full coverage dispatch below for complete documentation.
Key Takeaways
- Eli Lilly hikes sales outlook, as CEO says there's room for 'dramatic' obesity market expansion
- Eli Lilly reported that sales of obesity drug Zepbound and diabetes treatment Mounjaro surged again in the third quarter.
- Click full coverage link below for the complete official dispatch.
Eli Lilly reported that sales of obesity drug Zepbound and diabetes treatment Mounjaro surged again in the third quarter.
Original Publisher Attribution
This summary was curated from CNBC.